-
The Boston Globe | Researchers at the Broad Institute of MIT and Harvard are trying to find new life-saving uses for drugs first developed to cure other diseases.
May 14, 2018
-
Diagnostics World Brief | In an abstract published today at the Heart Rhythm Scientific Sessions conference in Boston, investigators from Mayo Clinic presented research showing that artificial intelligence using deep neural networks can successfully identify patients with congenital Long QT Syndrome despite having a normal QTc on their electrocardiogram.
May 10, 2018
-
Diagnostics World Brief | A tool to accurately determine which early-stage patients are at risk of dying from MF and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women’s Hospital have found that next-generation, high-throughput sequencing of a specific gene is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. The team’s results are published this week in Science Translational Medicine.
May 9, 2018
-
Bio-IT World | The National Institutes of Health opened national enrollment for the All of Us Research Program this weekend with a nationwide launch featuring events in New York; Birmingham, Ala.; Nashville, Tenn.; Detroit, Mi.; Kansas City, Mo.; Chicago; and Pasco, Wash. The launch events were broadcast on the All of Us website and Facebook live.
May 7, 2018
-
Bio-IT World |
BGI announced two partnerships today with Sinai Health System in Toronto and Johns Hopkins University. For the Sinai partnership, BGI plans to install two BGISEQ-500 platforms to work on diagnostics for pre-term labor.
May 4, 2018
-
Diagnostics World | For patients presenting in the emergency room with chest pain, troponins are exquisitely sensitive markers of myocardial injury. Physicians can therefore quickly intervene—with aspirin, beta blockers or a procedure in the cath lab—to limit damage to the heart and preserve cardiac function. But should patients need heart surgery or percutaneous coronary intervention, the heart isn’t the only organ at risk. Such procedures can put the kidneys at particular risk as well. Unfortunately, identifying and intervening in acute kidney injury isn’t quite as easy.
May 2, 2018
-
Diagnostics World News Brief | Thermo Fisher Scientific announced new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development programs at each of the firms. The agreements will focus on validating additional biomarkers and gene variants on the test and support Thermo Fisher's commitment to further enable precision oncology.
May 1, 2018
-
Diagnostics World | April featured news, products, and partnerships from around the diagnostics community from numerous companies, universities, and organizations, including Foundation Medicine, QIAGEN, Curetis, and more.
Apr 30, 2018
-
Diagnostics World Brief | Foundation Medicine, Roche, and DIAN Diagnostics announced a three-party collaboration to integrate Foundation Medicine’s comprehensive genomic profiling (CGP) assays into clinical patient care in mainland China.
Apr 27, 2018
-
Xconomy | The gene-editing technology CRISPR-Cas9 has captured the world’s attention with the possibility of fixing tough diseases and altering human traits. While experimental medicine, ethical worries, and an epic patent battle have attracted most of the headlines, the field’s pioneers have advanced new types of CRISPR to detect and diagnose diseases. Enter, a new diagnostics company called Mammoth Biosciences, which has licensed technology from the lab of Jennifer Doudna of the University of California, Berkeley.
Apr 26, 2018
-
Diagnostics World | During HudsonAlpha’s Genomic Medicine Conference, Tom May and Whitley Kelley spoke to the effect genomic and genetic testing have on both the patients and their families that might not always be addressed.
Apr 24, 2018
-
STAT | A biomedical tattoo that changes color when calcium in the blood is too high could one day be used to monitor for the earliest signs of cancer, scientists report in a new study.
Apr 18, 2018
-
Diagnostics World | Engineers at the New York Genome Center have designed a low-cost droplet microfluidic control instrument that can be 3-D printed and deployed in a clinical environment to perform single-cell transcriptome profiling. In a Nature Communications paper published in February, researchers from the Hospital for Special Surgery (HSS) in New York and the NYGC describe how the instrument, dubbed miniDrops, was developed and validated and used to analyze the gene expression of single-cells from the joints of five rheumatoid arthritis patients.
Apr 18, 2018